

An immune-active tumor microenvironment favors clin

Cancer Immunology, Immunotherapy

61, 1019-1031

DOI: [10.1007/s00262-011-1172-6](https://doi.org/10.1007/s00262-011-1172-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. <i>Science Translational Medicine</i> , 2012, 4, 127ra37.	5.8	1,837
2	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. <i>OncImmunology</i> , 2012, 1, 609-617.	2.1	67
4	Whole Genome and Exome Sequencing of Melanoma. <i>Advances in Pharmacology</i> , 2012, 65, 399-435.	1.2	10
5	Ipilimumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1511-1521.	1.1	6
6	The blockade of immune checkpoints in cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2012, 12, 252-264.	12.8	10,874
7	Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. <i>Journal of Translational Medicine</i> , 2013, 11, 75.	1.8	142
8	Immune-suppressive properties of the tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1137-1148.	2.0	179
9	Up-Regulation of PD-L1, IDO, and T _{regs} in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells. <i>Science Translational Medicine</i> , 2013, 5, 200ra116.	5.8	1,447
10	Rational combinations of immunotherapeutics that target discrete pathways. , 2013, 1, 16.		62
11	Primer on tumor immunology and cancer immunotherapy. , 2013, 1, 12.		63
12	Innate and adaptive immune cells in the tumor microenvironment. <i>Nature Immunology</i> , 2013, 14, 1014-1022.	7.0	3,109
13	Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions. <i>Current Oncology Reports</i> , 2013, 15, 500-508.	1.8	20
14	From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. <i>Current Opinion in Immunology</i> , 2013, 25, 261-267.	2.4	444
15	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. <i>Immunity</i> , 2013, 39, 11-26.	6.6	700
16	Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 387-401.	1.3	17
17	Cancer immunotherapy: accomplishments to date and future promise. <i>Therapeutic Delivery</i> , 2013, 4, 1307-1320.	1.2	106
18	Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4252-4259.	0.8	232
19	Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. <i>Oncologist</i> , 2013, 18, 717-725.	1.9	72

#	ARTICLE	IF	CITATIONS
21	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 268-276.	2.4	352
22	Functionalized carbon nanotubes as immunomodulator systems. <i>Biomaterials</i> , 2013, 34, 4395-4403.	5.7	109
23	At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2013, 94, 41-53.	1.5	305
24	Immunomodulatory therapy for melanoma: Ipilimumab and beyond. <i>Clinics in Dermatology</i> , 2013, 31, 191-199.	0.8	57
25	Prediction of Response to Anticancer Immunotherapy Using Gene Signatures. <i>Journal of Clinical Oncology</i> , 2013, 31, 2369-2371.	0.8	56
26	Molecular Profiling of Immunotherapeutic Resistance. , 2013, , 373-394.		2
27	Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. <i>Scientifica</i> , 2013, 2013, 1-19.	0.6	186
28	Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2388-2395.	0.8	327
29	Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study. <i>Cancer Investigation</i> , 2013, 31, 336-345.	0.6	55
30	Tremelimumab: a review of development to date in solid tumors. <i>Immunotherapy</i> , 2013, 5, 215-229.	1.0	55
31	Re-orienting the immune system. <i>Onc Immunology</i> , 2013, 2, e23661.	2.1	29
32	CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. <i>British Journal of Cancer</i> , 2013, 109, 2412-2423.	2.9	136
33	Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. <i>Cancer Immunology Research</i> , 2013, 1, 32-42.	1.6	726
34	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. <i>Journal of Experimental Medicine</i> , 2013, 210, 1389-1402.	4.2	562
36	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. <i>Frontiers in Immunology</i> , 2013, 4, 417.	2.2	62
37	Meta-analysis and metagenes. <i>Onc Immunology</i> , 2014, 3, e28727.	2.1	12
38	Biomarkers in melanoma: where are we now?. <i>Melanoma Management</i> , 2014, 1, 139-150.	0.1	1
39	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 663-686.	1.4	17

#	ARTICLE	IF	CITATIONS
40	Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. <i>Future Oncology</i> , 2014, 10, 1559-1570.	1.1	17
41	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. <i>Oncolmmunology</i> , 2014, 3, e27560.	2.1	38
42	Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme. <i>British Journal of Cancer</i> , 2014, 110, 2955-2964.	2.9	16
43	Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. <i>Cancer Immunology Research</i> , 2014, 2, 812-821.	1.6	122
44	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2189-2199.	13.9	3,753
45	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. <i>Science Translational Medicine</i> , 2014, 6, 226ra32.	5.8	590
46	Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. <i>Clinical Cancer Research</i> , 2014, 20, 3310-3318.	3.2	29
47	Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients. <i>Science Translational Medicine</i> , 2014, 6, 238ra70.	5.8	348
48	Harnessing the immune system for cancer therapy. <i>Current Opinion in Oncology</i> , 2014, 26, 600-607.	1.1	25
49	The Immune Microenvironment: A Major Player in Human Cancers. <i>International Archives of Allergy and Immunology</i> , 2014, 164, 13-26.	0.9	63
50	Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer. <i>Oncolmmunology</i> , 2014, 3, e944056.	2.1	1
51	Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 ⁺ T-cell response, prominent infiltration of CD8 ⁺ lymphocytes and Th1 type polarization. <i>Oncolmmunology</i> , 2014, 3, e958937.	2.1	39
52	Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 74.	2.2	39
53	Evaluating biomarkers in melanoma. <i>Frontiers in Oncology</i> , 2014, 4, 383.	1.3	38
54	Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis. <i>PLoS ONE</i> , 2014, 9, e109760.	1.1	192
55	A personalized view on cancer immunotherapy. <i>Cancer Letters</i> , 2014, 352, 113-125.	3.2	63
56	New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. <i>Current Opinion in Immunology</i> , 2014, 27, 16-25.	2.4	1,163
57	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 247-257.	2.0	472

#	ARTICLE	IF	CITATIONS
58	Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?. <i>British Journal of Dermatology</i> , 2014, 171, 987-995.	1.4	63
59	Immune Modulation in Cancer with Antibodies. <i>Annual Review of Medicine</i> , 2014, 65, 185-202.	5.0	455
61	STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. <i>Immunity</i> , 2014, 41, 830-842.	6.6	1,325
62	Acquired and intrinsic resistance in cancer immunotherapy. <i>Molecular Oncology</i> , 2014, 8, 1132-1139.	2.1	153
63	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1219-1228.	1.1	1
64	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5064-5074.	3.2	2,050
65	Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development. <i>BioDrugs</i> , 2014, 28, 421-437.	2.2	21
66	Combinatorial Approach to Treatment of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 601-612.	0.9	3
67	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14004.	2.0	33
68	Advances in molecular profiling of malignant melanoma: ready for clinical practice?. <i>Melanoma Management</i> , 2014, 1, 3-6.	0.1	0
69	Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 490-500.	1.5	134
70	Gene expression meta-analysis reveals immune response convergence on the IFN γ -STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. <i>Genome Medicine</i> , 2015, 7, 96.	3.6	24
71	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. <i>Oncotarget</i> , 2015, 6, 34221-34227.	0.8	198
72	Biomarkers of Response to Immune Modulatory Therapies in Cancer. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	1
73	Immunity, inflammation, and cancer: an eternal fight between good and evil. <i>Journal of Clinical Investigation</i> , 2015, 125, 3347-3355.	3.9	572
74	Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?. <i>Frontiers in Immunology</i> , 2015, 6, 411.	2.2	39
75	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. <i>Viruses</i> , 2015, 7, 5889-5901.	1.5	19
76	Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- α but Not Observation in Intermediate Risk Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0132745.	1.1	9

#	ARTICLE	IF	CITATIONS
77	Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. <i>Sarcoma</i> , 2015, 2015, 1-9.	0.7	48
78	Clinical Development of Immune Checkpoint Inhibitors. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	51
79	Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	17
80	Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. <i>Seminars in Oncology</i> , 2015, 42, 573-586.	0.8	21
81	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1075-1082.	2.0	16
82	Immunotherapy Not Working? Check Your Microbiota. <i>Cancer Cell</i> , 2015, 28, 687-689.	7.7	43
84	Talimogene laherparepvec in the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1517-1530.	1.4	8
85	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 99-127.	0.2	4
86	Therapeutic Antibodies in Cancer Therapy. , 2015, , 95-120.		1
87	Prognostic and predictive immune gene signatures in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 433-444.	1.1	75
88	Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab. <i>Cancer Research</i> , 2015, 75, 5084-5092.	0.4	46
89	Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1487-1494.	2.0	51
90	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	5.7	143
91	Innate Immune Recognition of Cancer. <i>Annual Review of Immunology</i> , 2015, 33, 445-474.	9.5	431
92	New perspectives on type I IFNs in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 175-178.	3.2	50
93	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 1974-1982.	0.8	2,220
94	Immune checkpoint modulation: Rational design of combination strategies. , 2015, 150, 23-32.		76
95	Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. <i>Cell</i> , 2015, 160, 48-61.	13.5	2,948

#	ARTICLE	IF	CITATIONS
96	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. <i>Advances in Cancer Research</i> , 2015, 128, 263-307.	1.9	123
97	What to expect from high throughput genomics in metastatic breast cancers?. <i>Breast</i> , 2015, 24, S19-S22.	0.9	4
98	Immune Checkpoint Inhibition in Renal Cell Carcinoma. , 2015, , 259-279.		0
99	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	12.8	576
100	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. , 2015, , 709-738.e8.		0
101	Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 755-763.	1.1	28
102	Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. <i>Clinical Investigation</i> , 2015, 5, 75-87.	0.0	1
103	Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease. <i>Annals of Surgical Oncology</i> , 2015, 22, 1950-1958.	0.7	16
105	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 399-411.	1.6	387
106	Immunotherapy for canine cancer – Is it time to go back to the future?. <i>Journal of Small Animal Practice</i> , 2015, 56, 229-241.	0.5	8
107	An infrared spectral signature of human lymphocyte subpopulations from peripheral blood. <i>Analyst</i> , 2015, 140, 2257-2265.	1.7	13
108	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015, 7, 280sr1.	5.8	134
109	Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. <i>Nature</i> , 2015, 523, 231-235.	18.7	2,130
110	The STING pathway and the T cell-inflamed tumor microenvironment. <i>Trends in Immunology</i> , 2015, 36, 250-256.	2.9	190
111	Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 244-252.	0.7	127
112	Immune-priming of the Tumor Microenvironment by Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 90-97.	0.6	79
113	Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies. <i>Seminars in Oncology</i> , 2015, 42, 448-458.	0.8	22
114	<i>In vivo</i> profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. <i>Oncolimmunology</i> , 2015, 4, e988458.	2.1	12

#	ARTICLE	IF	CITATIONS
115	Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti-PD-L1 efficacy. <i>Science</i> , 2015, 350, 1084-1089.	6.0	2,782
116	The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. <i>Seminars in Oncology</i> , 2015, 42, 663-671.	0.8	388
118	Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. <i>Journal of Controlled Release</i> , 2015, 216, 149-157.	4.8	157
119	Characterization of the <i>in vivo</i> immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. <i>Oncolmmunology</i> , 2015, 4, e982382.	2.1	95
120	Breast cancer and immunology: biomarker and therapeutic developments. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1215-1222.	1.1	9
121	Malaria parasites target the hepatocyte receptor EphA2 for successful host infection. <i>Science</i> , 2015, 350, 1089-1092.	6.0	119
122	Combination of Radiotherapy and Immune Checkpoint Inhibitors. <i>Seminars in Radiation Oncology</i> , 2015, 25, 28-33.	1.0	121
123	The Non-Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 377-390.	2.5	204
124	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e116-e122.	1.8	65
125	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 7.	0.3	3
126	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	0.9	36
127	Clinical utility of nivolumab in the treatment of advanced melanoma. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 313.	0.9	16
128	Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. <i>Frontiers in Immunology</i> , 2015, 6, 663.	2.2	74
129	Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. <i>Biomedicines</i> , 2016, 4, 21.	1.4	11
130	Immune Checkpoint Therapy in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 73-80.	1.0	10
131	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. <i>Immunotherapy</i> , 2016, 8, 821-837.	1.0	139
132	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	31
133	The role of immune checkpoint inhibition in the treatment of ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 11.	3.6	118

#	ARTICLE	IF	CITATIONS
134	Interferon- β and Tumor Necrosis Factor- α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. <i>Scientific Reports</i> , 2016, 6, 26345.	1.6	69
135	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e542-e551.	5.1	1,274
137	Disentangling the relationship between tumor genetic programs and immune responsiveness. <i>Current Opinion in Immunology</i> , 2016, 39, 150-158.	2.4	57
138	Therapeutic Antibodies in Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 917, 95-120.	0.8	36
139	Molecular Drivers of the Non- α T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 563-568.	1.6	293
140	The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma. , 2016, , 31-65.		0
141	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 313-341.	9.6	15
142	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. <i>Trends in Immunology</i> , 2016, 37, 462-476.	2.9	232
143	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	12.8	2,133
144	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 1865-1874.	3.2	700
145	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 879-893.	1.3	8
146	Biomarkers associated with checkpoint inhibitors. <i>Annals of Oncology</i> , 2016, 27, 1199-1206.	0.6	142
147	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>International Immunology</i> , 2016, 28, 373-382.	1.8	143
148	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5461-5471.	3.2	234
149	Radiotherapy: Changing the Game in Immunotherapy. <i>Trends in Cancer</i> , 2016, 2, 286-294.	3.8	270
150	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1490.	3.4	68
151	VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 858-868.	1.6	73
152	High-content molecular profiling of T-cell therapy in oncology. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16009.	2.0	6

#	ARTICLE	IF	CITATIONS
153	Clinical Response of a Patient to Anti- α PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 903-909.	1.6	45
154	HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?. <i>Epigenomics</i> , 2016, 8, 1015-1017.	1.0	22
155	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	1.4	107
157	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2016, 5, e1249559.	2.1	51
158	Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. <i>Scientific Reports</i> , 2016, 6, 31745.	1.6	22
159	Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 ⁺ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7240-E7249.	3.3	187
160	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37
161	Interferon- γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 650-657.	1.6	22
162	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	1.6	81
164	PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. <i>Oncolmmunology</i> , 2016, 5, e1176653.	2.1	59
165	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 943-955.	5.1	293
166	Checkpoint Inhibitors and Their Application in Breast Cancer. <i>Breast Care</i> , 2016, 11, 108-115.	0.8	45
167	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
168	Synergistic COX2 Induction by IFN γ and TNF α Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2016, 4, 303-311.	1.6	53
169	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. <i>Cancer Treatment Reviews</i> , 2016, 43, 113-123.	3.4	9
170	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 231-250.	0.2	36
171	Prognostic and predictive biomarkers in melanoma: an update. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 223-237.	1.5	23
172	Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. <i>Seminars in Immunology</i> , 2016, 28, 54-63.	2.7	47

#	ARTICLE	IF	CITATIONS
173	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	3.2	353
174	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
175	Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN γ Combined with Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3791-3800.	3.2	77
176	Anti-CTLA-4 Ab. , 2016, , 263-282.		2
177	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	1.8	39
178	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4119-4132.	3.2	266
179	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 833-842.	0.8	517
180	Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?. <i>Biochemical Pharmacology</i> , 2016, 102, 1-6.	2.0	119
181	Dehydroleucodine inhibits tumor growth in a preclinical melanoma model by inducing cell cycle arrest, senescence and apoptosis. <i>Cancer Letters</i> , 2016, 372, 10-23.	3.2	15
182	Metastatic melanoma treatment: Combining old and new therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 242-253.	2.0	64
183	Identification of melanoma cells and lymphocyte subpopulations in lymph node metastases by FTIR imaging histopathology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 202-212.	1.8	28
184	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. <i>Oncogene</i> , 2016, 35, 3209-3216.	2.6	260
185	Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells. <i>Cancer Research</i> , 2017, 77, 1623-1636.	0.4	13
186	Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. <i>Cancer Immunology Research</i> , 2017, 5, 170-179.	1.6	23
187	Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 81-90.	1.0	0
189	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncimmunology</i> , 2017, 6, e1253654.	2.1	146
190	TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. <i>Immunological Reviews</i> , 2017, 276, 165-177.	2.8	125
191	Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e389-e391.	1.3	21

#	ARTICLE	IF	CITATIONS
192	Targeting the immune system in glioblastoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 121-131.	0.4	0
193	The swinging pendulum of cancer immunotherapy personalization. Personalized Medicine, 2017, 14, 259-270.	0.8	3
194	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-“Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research, 2017, 77, 3540-3550.	0.4	327
195	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1977-1984.	1.2	14
196	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017, 153, 812-826.	0.6	650
197	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncology, 2017, 70, 34-42.	0.8	38
198	Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 544.e25-544.e31.	0.8	9
199	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K γ /I β . Cancer Research, 2017, 77, 2607-2619.	0.4	165
200	Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nature Reviews Clinical Oncology, 2017, 14, 463-482.	12.5	945
201	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	7.7	48
202	Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. OncoImmunology, 2017, 6, e1306617.	2.1	5
203	UV-induced somatic mutations elicit a functional T cell response in the YUMMER 1.7 mouse melanoma model. Pigment Cell and Melanoma Research, 2017, 30, 428-435.	1.5	143
204	Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 281-293.	1.4	16
205	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point ¹⁸ F-FDG PET/CT Imaging in Patients with Advanced Melanoma. Journal of Nuclear Medicine, 2017, 58, 1421-1428.	2.8	209
206	Biomarkers and Immunotherapeutic Targets in Glioblastoma. World Neurosurgery, 2017, 102, 494-506.	0.7	29
207	Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?. Clinical and Translational Immunology, 2017, 6, e134.	1.7	32
208	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunology Research, 2017, 5, 29-41.	1.6	321
209	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology, 2017, 152, 745-761.	0.6	838

#	ARTICLE	IF	CITATIONS
210	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 264-272.	21.5	204
211	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	1.6	126
212	Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells. <i>Cancer Science</i> , 2017, 108, 2333-2341.	1.7	9
213	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017, 8, 592.	5.8	166
214	Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	174
215	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. <i>Clinical Cancer Research</i> , 2017, 23, 4980-4991.	3.2	14
216	CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1449-1461.	2.0	69
217	Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. <i>ESMO Open</i> , 2017, 2, e000213.	2.0	248
218	The importance for immunoregulation for long-term cancer control. <i>Future Oncology</i> , 2017, 13, 1619-1632.	1.1	9
219	The Immunology of Melanoma. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 449-471.	0.7	34
220	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
221	Migrating into the Tumor: a Roadmap for T Cells. <i>Trends in Cancer</i> , 2017, 3, 797-808.	3.8	230
222	Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry. <i>Cancer Immunology Research</i> , 2017, 5, 1062-1073.	1.6	29
223	Biomarkers of response to PD-1/PD-L1 inhibition. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 116-124.	2.0	249
224	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
225	Gene-expression profiling to predict responsiveness to immunotherapy. <i>Cancer Gene Therapy</i> , 2017, 24, 134-140.	2.2	72
226	Immunotherapy of melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 594-603.	0.5	21
227	Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. <i>Oncolmmunology</i> , 2017, 6, e1231291.	2.1	29

#	ARTICLE	IF	CITATIONS
228	Combining Type I Interferons and 5-Aza-2-Deoxycytidine to Improve Anti-Tumor Response against Melanoma. <i>Journal of Investigative Dermatology</i> , 2017, 137, 159-169.	0.3	60
229	Tumor Immuno-Environment in Cancer Progression and Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 1-18.	0.8	31
230	High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. <i>Oncotarget</i> , 2017, 8, 49470-49483.	0.8	24
231	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	2.2	27
232	Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 136.	1.3	40
233	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Oncology</i> , 2017, 7, 233.	1.3	61
234	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	0.9	31
235	Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1797.	1.8	21
236	Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2983-2992.	1.0	46
237	The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. , 2017, 5, 63.		61
238	Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. <i>Oncotarget</i> , 2017, 8, 55804-55820.	0.8	75
239	Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker Based Approaches. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2017, 08, .	0.4	25
240	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
241	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 429-445.	1.1	45
242	Molecular Tests for the Choice of Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2017, 23, 4794-4806.	0.9	10
243	Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. <i>JCI Insight</i> , 2017, 2, .	2.3	77
244	Towards predictive biomarkers for immunotherapy response in breast cancer patients. <i>Breast Cancer Management</i> , 2018, 7, BMT05.	0.2	4
245	Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. <i>Oncimmunology</i> , 2018, 7, e1450715.	2.1	48

#	ARTICLE	IF	CITATIONS
246	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018, 173, 305-320.e10.	13.5	272
247	Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: A large-scale cohort study. <i>International Journal of Cancer</i> , 2018, 142, 2558-2566.	2.3	73
248	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. <i>Oncogenesis</i> , 2018, 7, 2.	2.1	68
249	Expected Paradigm Shift in Brain Metastases Therapy—Immune Checkpoint Inhibitors. <i>Molecular Neurobiology</i> , 2018, 55, 7072-7078.	1.9	18
250	Cancer Systems Biology. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	8
251	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 189-200.	1.6	102
252	Profiling Tumor Infiltrating Immune Cells with CIBERSORT. <i>Methods in Molecular Biology</i> , 2018, 1711, 243-259.	0.4	1,936
254	Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. <i>Nature Protocols</i> , 2018, 13, 335-357.	5.5	32
255	Tumor-infiltrating lymphocytes are associated with β -catenin overexpression in breast cancer. <i>Cancer Biomarkers</i> , 2018, 21, 639-650.	0.8	9
256	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23
257	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. , 2018, , 231-246.		0
258	Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. <i>OncolImmunology</i> , 2018, 7, e1417721.	2.1	33
259	Impact of oncogenic pathways on evasion of antitumour immune responses. <i>Nature Reviews Cancer</i> , 2018, 18, 139-147.	12.8	506
260	Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. <i>Journal of Immunology</i> , 2018, 200, 432-442.	0.4	153
261	Review of diagnostic, prognostic, and predictive biomarkers in melanoma. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 487-493.	1.7	26
262	Drug-Induced Sarcoidosis-Like Reactions. <i>Chest</i> , 2018, 154, 664-677.	0.4	131
263	Immune signatures predicting responses to immunomodulatory antibody therapy. <i>Current Opinion in Immunology</i> , 2018, 51, 91-96.	2.4	7
264	Do checkpoint inhibitors rely on gut microbiota to fight cancer?. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 468-472.	0.5	3

#	ARTICLE	IF	CITATIONS
265	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas. <i>JAMA Oncology</i> , 2018, 4, 93.	3.4	303
266	Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 141-151.	2.0	58
267	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy. <i>Cancer Treatment Reviews</i> , 2018, 63, 40-47.	3.4	867
268	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. <i>Cancer Immunology Research</i> , 2018, 6, 139-150.	1.6	172
269	Rho GTPase effectors and NAD metabolism in cancer immune suppression. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 9-17.	1.5	13
270	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. <i>Current Cancer Research</i> , 2018, , 1-28.	0.2	0
271	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	0.8	14
272	Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2661-2662.	0.8	9
273	Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 1611-1618.	0.8	448
274	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. <i>Medicine (United States)</i> , 2018, 97, e12344.	0.4	4
275	Combining immunotherapy and radiotherapy in lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1447-S1460.	0.6	54
276	Dendritic Cells: The Tools for Cancer Treatment. , 0, , .		4
277	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2480.	2.2	57
278	Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 155, 1936-1950.e17.	0.6	211
279	β-catenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. <i>BMC Cancer</i> , 2018, 18, 1062.	1.1	20
280	Analysis of PD-1 related immune transcriptional profile in different cancer types. <i>Cancer Cell International</i> , 2018, 18, 218.	1.8	15
281	Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2927.	2.2	102
282	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	1.2	67

#	ARTICLE	IF	CITATIONS
283	Oncolytic virus immunotherapy: future prospects for oncology. , 2018, 6, 140.		197
284	Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.	0.4	155
285	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	3.4	58
286	Potential function of CTLA-4 in the tumorigenic capacity of melanoma stem cells. <i>Oncology Letters</i> , 2018, 16, 6163-6170.	0.8	16
287	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 1383-1391.	2.9	54
288	Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8 ⁺ T-cell immune responses. <i>Cancer Management and Research</i> , 2018, Volume 10, 4113-4123.	0.9	43
289	A Comprehensive Survey of Immune Cytolytic Activity-Associated Gene Co-Expression Networks across 17 Tumor and Normal Tissue Types. <i>Cancers</i> , 2018, 10, 307.	1.7	4
290	T Cell-“Inflamed versus Non-T Cell-“Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. <i>Cancer Immunology Research</i> , 2018, 6, 990-1000.	1.6	297
291	Selecting immuno-oncology-“based drug combinations “ what should we be considering?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 971-985.	1.3	5
292	Stem cell fate in cancer growth, progression and therapy resistance. <i>Nature Reviews Cancer</i> , 2018, 18, 669-680.	12.8	458
293	Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. <i>ACS Nano</i> , 2018, 12, 9881-9893.	7.3	58
294	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
295	Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1076-1082.	0.5	143
296	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 426-434.e1.	1.1	102
297	Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. <i>Immunity</i> , 2018, 49, 178-193.e7.	6.6	502
298	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. <i>Mammalian Genome</i> , 2018, 29, 866-878.	1.0	10
299	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-“A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	2.2	174
300	The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. <i>Frontiers in Oncology</i> , 2018, 8, 27.	1.3	71

#	ARTICLE	IF	CITATIONS
301	Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance. <i>Frontiers in Oncology</i> , 2018, 8, 173.	1.3	123
302	Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 185.	1.3	60
303	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. <i>Biomedicines</i> , 2018, 6, 26.	1.4	16
304	Current Strategies to Enhance Anti-Tumour Immunity. <i>Biomedicines</i> , 2018, 6, 37.	1.4	11
305	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2018, 62, 29-39.	1.7	860
306	Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1340.	1.8	61
307	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
308	Autoantibodies as Potential Biomarkers in Breast Cancer. <i>Biosensors</i> , 2018, 8, 67.	2.3	36
309	Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioliomyomatosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 723-732.	1.4	37
310	Tertiary Lymphoid Structures. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	3
311	Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. <i>Methods in Molecular Biology</i> , 2018, 1845, 241-257.	0.4	18
312	Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. <i>Cancer Medicine</i> , 2018, 7, 4517-4529.	1.3	34
313	Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1673-1683.	2.0	42
314	Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site. <i>Cells</i> , 2018, 7, 108.	1.8	23
315	Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen. <i>Journal of Immunology</i> , 2018, 201, 1875-1888.	0.4	20
316	Combinatorial Approach to Treatment of Melanoma. , 2019, , 687-697.		0
317	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <i>Advances in Therapy</i> , 2019, 36, 2638-2678.	1.3	145
318	Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 364.	3.5	63

#	ARTICLE	IF	CITATIONS
319	Tissue Site and the Cancer Immunity Cycle. <i>Trends in Cancer</i> , 2019, 5, 593-603.	3.8	37
320	High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes. <i>Nature Communications</i> , 2019, 10, 3120.	5.8	202
321	Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	147
322	Oncolytic Viruses: Priming Time for Cancer Immunotherapy. <i>BioDrugs</i> , 2019, 33, 485-501.	2.2	90
323	Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019, 2, 100-109.	1.3	11
324	Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology. <i>Cancer Research</i> , 2019, 79, 4801-4807.	0.4	150
325	Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. <i>Cell</i> , 2019, 178, 585-599.e15.	13.5	162
326	Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. <i>Cancer Investigation</i> , 2019, 37, 265-274.	0.6	31
327	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
328	Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma. <i>Anticancer Research</i> , 2019, 39, 4995-5001.	0.5	9
329	WNT/ β -Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 2293.	2.2	165
330	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , 2019, 119, 151-157.	1.3	103
331	Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. <i>Cancers</i> , 2019, 11, 1217.	1.7	36
332	OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy. <i>Journal of Leukocyte Biology</i> , 2019, 105, 915-933.	1.5	22
333	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834.	1.7	41
334	Hyperprogression under Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2674.	1.8	96
335	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <i>Frontiers in Medicine</i> , 2019, 6, 119.	1.2	145
336	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2019, 8, e1581556.	2.1	68

#	ARTICLE	IF	CITATIONS
337	Intrinsic β -catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108921.	2.5	57
338	Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression. <i>Journal of Cellular Physiology</i> , 2019, 234, 22260-22271.	2.0	9
339	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. <i>Scientific Reports</i> , 2019, 9, 7449.	1.6	43
340	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 999.	2.2	47
341	STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. , 2019, 7, 115.		114
342	Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery. <i>Scientific Reports</i> , 2019, 9, 5562.	1.6	16
343	Multiple antigen-engineered DC vaccines with or without IFN γ to promote antitumor immunity in melanoma. , 2019, 7, 113.		31
344	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	6.9	58
345	The Ins and Outs of Chemokine-Mediated Immune Cell Trafficking in Skin Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 386.	2.2	11
346	Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.	15.2	346
347	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2019, 33, 159-171.	2.2	40
348	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	1.3	32
349	Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 2946-2952.	0.8	82
350	Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy. <i>Trends in Molecular Medicine</i> , 2019, 25, 412-427.	3.5	92
351	CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2379-2392.	3.3	29
352	Integrative immunologic and genomic characterization of brain metastasis from ovarian/peritoneal cancer. <i>Pathology Research and Practice</i> , 2019, 215, 152404.	1.0	9
353	Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. <i>Hepatology</i> , 2019, 70, 1437-1442.	3.6	104
354	Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 547-560.	1.4	6

#	ARTICLE	IF	CITATIONS
355	Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 333.	2.2	234
356	Clinical Trial Outcomes. <i>JACC: Heart Failure</i> , 2019, 7, 272-273.	1.9	6
357	Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. <i>Journal of Cancer</i> , 2019, 10, 120-130.	1.2	5
358	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
359	Targeting of the Cancer-Associated Fibroblast-T-Cell Axis in Solid Malignancies. <i>Journal of Clinical Medicine</i> , 2019, 8, 1989.	1.0	42
360	Melanoma and Vitiligo: In Good Company. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5731.	1.8	40
361	Recruitment of CD103 dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. <i>Science Advances</i> , 2019, 5, eaay1357.	4.7	87
362	In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma. <i>International Journal of Hyperthermia</i> , 2019, 36, 64-73.	1.1	29
363	Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. <i>Melanoma Research</i> , 2019, 29, 453-464.	0.6	26
364	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989028.	1.4	74
365	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
366	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 197-218.	21.5	2,005
367	Personalized Cancer Vaccine. , 2019, , 81-89.		0
368	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	0.5	68
369	Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer. <i>Immunopharmacology and Immunotoxicology</i> , 2019, 41, 386-393.	1.1	27
370	WNT/ β -catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3074-3083.	3.2	435
371	Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. <i>Annals of Oncology</i> , 2019, 30, 219-235.	0.6	340
372	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 95-102.	1.4	5

#	ARTICLE	IF	CITATIONS
373	Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophanâ€“Kynurenineâ€“Aryl Hydrocarbon Axis. <i>Clinical Cancer Research</i> , 2019, 25, 1462-1471.	3.2	271
374	Predictive biomarkers of response for immune checkpoint inhibitors in nonâ€“small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 106, 144-159.	1.3	164
375	Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repairâ€“Deficient Colon Cancers: Implications for Prognosis. <i>Clinical Cancer Research</i> , 2019, 25, 125-133.	3.2	57
376	A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy. <i>Oncolmunology</i> , 2019, 8, e1513440.	2.1	20
377	Tumor inherent interferons: Impact on immune reactivity and immunotherapy. <i>Cytokine</i> , 2019, 118, 42-47.	1.4	17
378	STING, DCs and the link between innate and adaptive tumor immunity. <i>Molecular Immunology</i> , 2019, 110, 13-23.	1.0	85
379	Nivolumab for the treatment of small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 5-13.	1.0	4
380	Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. <i>Methods in Enzymology</i> , 2020, 635, 149-166.	0.4	4
381	Biomarkers for immune checkpoint inhibition in nonâ€“small cell lung cancer (NSCLC). <i>Cancer</i> , 2020, 126, 260-270.	2.0	202
382	Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 390-402.	1.5	19
383	When food regimes become hegemonic: Agrarian India through a Gramscian lens. <i>Journal of Agrarian Change</i> , 2020, 20, 188-206.	0.8	8
384	Detection of neoantigen-reactive T cell clones based on the clonal expansion using next-generation sequencing of T cell receptor Î² complementarity-determining region 3. <i>Journal of Immunological Methods</i> , 2020, 476, 112679.	0.6	3
385	Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial. <i>British Journal of Cancer</i> , 2020, 123, 1616-1624.	2.9	17
386	Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7378.	1.8	62
387	Assessment of long non-coding RNA expression reveals novel mediators of the lung tumour immune response. <i>Scientific Reports</i> , 2020, 10, 16945.	1.6	16
388	Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 702.	2.0	8
389	Generation of highly activated, antigen-specific tumor-infiltrating CD8 ⁺ T cells induced by a novel T cell-targeted immunotherapy. <i>Oncolmunology</i> , 2020, 9, 1782574.	2.1	2
390	Cutaneous melanoma and the immunotherapy revolution (Review). <i>International Journal of Oncology</i> , 2020, 57, 609-618.	1.4	75

#	ARTICLE	IF	CITATIONS
391	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
392	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
393	Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1381.	1.3	10
394	Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 1590.	2.2	50
395	Comprehensive Analysis of the Immune Implication of ACK1 Gene in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1132.	1.3	20
396	Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations. <i>Future Oncology</i> , 2020, 16, 1665-1668.	1.1	1
398	Resident Memory T Cells in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 39-68.	0.8	3
399	Chemokine biology on immune checkpoint-targeted therapies. <i>European Journal of Cancer</i> , 2020, 137, 260-271.	1.3	13
400	Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. <i>Scientific Reports</i> , 2020, 10, 18336.	1.6	6
401	Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. <i>Biomarker Research</i> , 2020, 8, 34.	2.8	266
402	Combining immunotherapy and radiotherapy in lung cancer: a promising future?. <i>Journal of Thoracic Disease</i> , 2020, 12, 4498-4503.	0.6	7
403	Mucinous gastric adenocarcinoma: A good candidate for immune therapy?. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 624-625.	0.6	1
404	Nucleic Acid-Based Approaches for Tumor Therapy. <i>Cells</i> , 2020, 9, 2061.	1.8	40
405	Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. <i>Cell Death and Disease</i> , 2020, 11, 1062.	2.7	32
406	Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. <i>Radiation Oncology</i> , 2020, 15, 254.	1.2	62
407	Phase II study of β -galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer. , 2020, 8, e000316.		32
408	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
409	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 784.	2.2	339

#	ARTICLE	IF	CITATIONS
410	Comprehensive analysis of CTLA-4 in the tumor immune microenvironment of 33 cancer types. <i>International Immunopharmacology</i> , 2020, 85, 106633.	1.7	14
411	HDAC9 deficiency promotes tumor progression by decreasing the CD8 ⁺ dendritic cell infiltration of the tumor microenvironment. , 2020, 8, e000529.		22
412	Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 1414.	1.7	15
413	Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 348.	2.0	4
414	Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses. <i>Frontiers in Immunology</i> , 2020, 11, 990.	2.2	27
415	Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4071.	1.8	23
416	Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. <i>Clinical and Translational Medicine</i> , 2020, 10, 374-411.	1.7	33
417	Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 3652.	1.6	68
418	CXCL-10: a new candidate for melanoma therapy?. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 353-365.	2.1	37
419	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 223.	2.2	54
420	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. <i>Nanomaterials</i> , 2020, 10, 1274.	1.9	26
421	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. <i>Seminars in Cancer Biology</i> , 2022, 79, 18-43.	4.3	35
422	Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?. <i>Cells</i> , 2020, 9, 1525.	1.8	13
423	Tumor Microenvironments in Organs. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	2
424	Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4 ⁺ tumor infiltrating lymphocytes and their in situ localization. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 653-662.	2.0	16
425	The emerging development of tumor mutational burden in patients with NSCLC. <i>Future Oncology</i> , 2020, 16, 469-481.	1.1	2
426	Tumor-Derived Lactic Acid Contributes to the Paucity of Intratumoral ILC2s. <i>Cell Reports</i> , 2020, 30, 2743-2757.e5.	2.9	48
427	The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 519.	1.0	26

#	ARTICLE	IF	CITATIONS
428	Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. <i>Cancer Biology and Therapy</i> , 2020, 21, 432-440.	1.5	20
429	Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy. <i>Oncolmmunology</i> , 2020, 9, 1715767.	2.1	14
430	Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	117
431	The G protein coupled receptor CCR5 in cancer. <i>Advances in Cancer Research</i> , 2020, 145, 29-47.	1.9	15
432	Directing Traffic: How to Effectively Drive T Cells into Tumors. <i>Cancer Discovery</i> , 2020, 10, 185-197.	7.7	68
433	Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma. <i>International Immunopharmacology</i> , 2020, 80, 106211.	1.7	1
434	Prognostic value of the expression of chemokines and their receptors in regional lymph nodes of melanoma patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3407-3418.	1.6	12
435	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. <i>Immunity</i> , 2020, 52, 36-54.	6.6	127
436	<i>PRKDC</i> : new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
437	Lifting the innate immune barriers to antitumor immunity. , 2020, 8, e000695.		50
438	IL-10 suppresses IFN- γ -mediated signaling in lung adenocarcinoma. <i>Clinical and Experimental Medicine</i> , 2020, 20, 449-459.	1.9	9
439	An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. <i>Oncolmmunology</i> , 2020, 9, 1738812.	2.1	38
440	A Th1/IFN γ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1725-1735.	3.2	13
441	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504.	3.2	355
442	Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 405-415.	2.0	8
443	The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1407-1416.	0.7	4
444	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. <i>Translational Oncology</i> , 2021, 14, 100977.	1.7	13
445	Anti-tumour immunity induces aberrant peptide presentation in melanoma. <i>Nature</i> , 2021, 590, 332-337.	13.7	81

#	ARTICLE	IF	CITATIONS
446	Cutaneous sarcoidâ€like drug reaction caused by an anaplastic lymphoma kinase inhibitor. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 425-428.	0.7	1
447	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. <i>Advanced Therapeutics</i> , 2021, 4, 2000147.	1.6	2
448	Combining radiation therapy and immunotherapy for lung cancers: a narrative review. <i>Shanghai Chest</i> , 2021, 5, 10-10.	0.3	4
449	Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 612202.	2.2	66
450	Network- and systems-based re-engineering of dendritic cells with non-coding RNAs for cancer immunotherapy. <i>Theranostics</i> , 2021, 11, 1412-1428.	4.6	8
451	Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. <i>Theranostics</i> , 2021, 11, 3089-3108.	4.6	207
452	The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 210.	1.7	86
453	Construction and validation of a novel prognostic signature for uveal melanoma based on five metabolism-related genes. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 8045-8063.	1.0	3
454	Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. , 2021, 9, e001615.		18
455	Key chemokines direct migration of immune cells in solid tumors. <i>Cancer Gene Therapy</i> , 2022, 29, 10-21.	2.2	186
456	Wnt/ β -Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. <i>Cancers</i> , 2021, 13, 889.	1.7	24
457	Targeting Innate Immunity in Cancer Therapy. <i>Vaccines</i> , 2021, 9, 138.	2.1	57
458	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 74.	3.5	19
459	Copperâ€Based Nanoscale Coordination Polymers Augmented Tumor Radioimmunotherapy for Immunogenic Cell Death Induction and Tâ€Cell Infiltration. <i>Small</i> , 2021, 17, e2006231.	5.2	50
460	A Prognostic Signature Based on Immunogenomic Profiling Offers Guidance for Esophageal Squamous Cell Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 603634.	1.3	8
461	Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates. <i>Annals of Translational Medicine</i> , 2021, 9, 465-465.	0.7	14
462	T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A⁺CD141⁺ cDC1 and CD14⁺ antigen-presenting cell recruitment. , 2021, 9, e001962.		9
463	Immunotherapy and predictive immunologic profile: the tip of the iceberg. <i>Medical Oncology</i> , 2021, 38, 51.	1.2	4

#	ARTICLE	IF	CITATIONS
464	Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. <i>Neoplasia</i> , 2021, 23, 281-293.	2.3	18
465	Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 6731.	1.6	5
466	RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 642159.	1.3	30
467	Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. , 2021, 9, e001506.		23
468	Defining Immunogenic and Radioimmunogenic Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 667075.	1.3	22
469	Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 596484.	1.8	7
470	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3556-3566.	3.2	21
471	PTEN loss correlates with T cell exclusion across human cancers. <i>BMC Cancer</i> , 2021, 21, 429.	1.1	38
472	Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 1819.	1.7	16
473	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. <i>Brain</i> , 2021, 144, 1046-1066.	3.7	24
474	An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4464.	1.8	8
475	Nonsense-mediated RNA decay and its bipolar function in cancer. <i>Molecular Cancer</i> , 2021, 20, 72.	7.9	40
476	Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 1607-1619.	0.6	10
477	Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2193-2204.	1.3	16
478	Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 206-218.	2.1	7
479	Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses. <i>Journal of Translational Medicine</i> , 2021, 19, 222.	1.8	9
480	Multiomics characteristics of neurogenesis-related gene are dysregulated in tumor immune microenvironment. <i>Npj Genomic Medicine</i> , 2021, 6, 37.	1.7	7
481	Motility Matters: How CD8 ⁺ T-Cell Trafficking Influences Effector and Memory Cell Differentiation. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a038075.	2.3	2

#	ARTICLE	IF	CITATIONS
482	Identification of Precise Therapeutic Targets and Characteristic Prognostic Genes Based on Immune Gene Characteristics in Uveal Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666462.	1.8	2
483	Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment. <i>Experimental Hematology and Oncology</i> , 2021, 10, 31.	2.0	25
484	Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications. <i>Cancer Medicine</i> , 2021, 10, 5358-5374.	1.3	3
485	Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. <i>Immunological Reviews</i> , 2021, 302, 241-258.	2.8	87
486	Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment. <i>Neuroendocrinology</i> , 2022, 112, 370-383.	1.2	5
487	Novel anti-4-1BB α -PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. , 2021, 9, e002428.		26
488	Carnosic acid-induced co-self-assembly of metal-peptide complexes into a nanocluster-based framework with tumor-specific accumulation for augmented immunotherapy. <i>Chemical Engineering Journal</i> , 2021, 416, 129141.	6.6	19
489	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1253-1266.	1.3	13
490	LDH α negatively regulates dMMR in colorectal cancer. <i>Cancer Science</i> , 2021, 112, 3050-3063.	1.7	14
491	Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. , 2021, 9, e002417.		21
492	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , .		4
493	MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. , 2021, 9, e002528.		45
494	NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. <i>Nature Communications</i> , 2021, 12, 4536.	5.8	51
495	A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 725223.	2.2	24
496	The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications. <i>Genes and Diseases</i> , 2022, 9, 1208-1219.	1.5	9
497	Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. <i>Laboratory Investigation</i> , 2021, 101, 1561-1570.	1.7	15
498	N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 718644.	1.3	15
499	Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma. <i>International Immunopharmacology</i> , 2021, 97, 107817.	1.7	10

#	ARTICLE	IF	CITATIONS
500	Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. <i>Dermatology and Therapy</i> , 2021, 11, 1481-1496.	1.4	12
501	Circadian disruption induced by tumor development in a murine model of melanoma. <i>Chronobiology International</i> , 2021, , 1-14.	0.9	2
502	Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1243-1255.	2.1	7
503	Clinical translation and challenges in cancer immunotherapies. , 2022, , 469-490.		0
504	Nucleic acid biomarker technology for cancer immunotherapy. , 2022, , 331-356.		0
505	Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?. <i>Current Cancer Research</i> , 2021, , 27-54.	0.2	0
507	Noninvasive Imaging of Cancer Immunotherapy. <i>Nanotheranostics</i> , 2021, 5, 90-112.	2.7	22
508	Functional Annotation of Differentially Regulated Gene Set Using WebGestalt: A Gene Set Predictive of Response to Ipilimumab in Tumor Biopsies. <i>Methods in Molecular Biology</i> , 2014, 1101, 31-42.	0.4	17
509	Cancer Stem Cell Niche and Immune-Active Tumor Microenvironment in Testicular Germ Cell Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1226, 111-121.	0.8	16
510	Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 503-512.	1.1	11
511	Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. <i>Journal of Cell Biology</i> , 2020, 219, .	2.3	42
513	Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2018, 24, 4820-4833.	3.2	225
514	Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. <i>JCI Insight</i> , 2017, 2, .	2.3	48
515	DNA repair defects and implications for immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 4236-4242.	3.9	59
516	Lung tumor NF- κ B signaling promotes T cell-mediated immune surveillance. <i>Journal of Clinical Investigation</i> , 2013, 123, 2509-2522.	3.9	102
517	Lymphatic vessels regulate immune microenvironments in human and murine melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3389-3402.	3.9	157
518	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2015, 125, 3377-3383.	3.9	146
519	Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. <i>Journal of Clinical Investigation</i> , 2016, 126, 3130-3144.	3.9	773

#	ARTICLE	IF	CITATIONS
520	The host STING pathway at the interface of cancer and immunity. <i>Journal of Clinical Investigation</i> , 2016, 126, 2404-2411.	3.9	327
521	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	0.8	14
522	Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. <i>PLoS ONE</i> , 2017, 12, e0179726.	1.1	216
523	Melanoma Immunotherapy: Mechanisms and Opportunities. <i>Investigative Dermatology and Venereology Research</i> , 2016, 2, 1-7.	0.1	1
524	Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes. <i>Aging</i> , 2020, 12, 12187-12205.	1.4	13
525	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	0.8	93
526	Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the <i>JAK2</i> gene in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 60975-60986.	0.8	15
527	Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. <i>Oncotarget</i> , 2018, 9, 4375-4384.	0.8	26
528	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 12452-12470.	0.8	73
529	Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype. <i>Oncotarget</i> , 2018, 9, 11126-11144.	0.8	11
530	Survival correlation of immune response in human cancers. <i>Oncotarget</i> , 2019, 10, 6885-6897.	0.8	3
531	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , 2015, 6, 12297-12309.	0.8	148
532	p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways. <i>Oncotarget</i> , 2015, 6, 16963-16980.	0.8	21
533	A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. <i>Oncotarget</i> , 2015, 6, 28999-29015.	0.8	53
534	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	0.8	134
535	Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 376-376.	0.7	79
536	Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 389-389.	0.7	26
537	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. <i>Current Drug Targets</i> , 2017, 18, 315-331.	1.0	39

#	ARTICLE	IF	CITATIONS
538	Tumor-intrinsic response to IFN γ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Science Alliance, 2019, 2, e201900328.	1.3	38
539	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 748.	1.4	16
540	The inflammatory microenvironment in brain metastases: potential treatment target?. Chinese Clinical Oncology, 2015, 4, 21.	0.4	51
541	Predictive factors for immunotherapy in melanoma. Annals of Translational Medicine, 2015, 3, 208.	0.7	27
542	Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of Translational Medicine, 2015, 3, 267.	0.7	47
543	The effects of age and systemic metabolism on anti-tumor T cell responses. ELife, 2020, 9, .	2.8	34
544	Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma. BioMed Research International, 2021, 2021, 1-18.	0.9	4
545	The GPR171 pathway suppresses T cell activation and limits antitumor immunity. Nature Communications, 2021, 12, 5857.	5.8	11
546	Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy. , 2015, , 427-439.		0
547	Clinical Success of Adoptive Cell Transfer Therapy Using Tumor Infiltrating Lymphocytes. Cancer Drug Discovery and Development, 2015, , 151-181.	0.2	0
550	Combinatorial Approach to Treatment of Melanoma. , 2018, , 1-11.		0
551	Front line of cancer immunotherapy development. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 2645-2658.	0.0	0
553	Mechanisms of resistance to anti-Pd-1 therapy in metastatic cutaneous melanoma. , 2018, 17, 34-46.	0.3	2
554	Toxicités sévères des immunothérapies du cancer. Medecine Intensive Reanimation, 2018, 27, 522-536.	0.1	0
555	Novel Immunotherapies and Novel Combinations of Immunotherapy. , 2019, , 1-22.		0
556	Clinicopathological correlation of immune response in human cancers. Oncotarget, 2019, 10, 5859-5870.	0.8	0
558	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
559	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	1.7	13

#	ARTICLE	IF	CITATIONS
560	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 247-258.	2.9	14
561	Synergy between <i>Toxoplasma gondii</i> type I ⁺ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. , 2021, 9, e002970.		19
562	Companion Diagnostics and Clinical Biomarkers for Immunotherapy. , 2021, , 137-152.		0
563	Prognostic Hub Genes in the Immune Microenvironment of Lung Adenocarcinoma by Estimation. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021, 25, 77-89.	0.6	0
564	Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1277, 127-141.	0.8	0
565	Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. , 2020, , 1165-1186.		0
568	Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma. <i>Aging</i> , 2021, 13, 24155-24170.	1.4	1
571	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0
572	CTLA-4 blockade in tumor models: an overview of preclinical and translational research. <i>Cancer Immunity</i> , 2013, 13, 5.	3.2	220
573	Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. <i>Oncology</i> , 2015, 29, 908-20, 922.	0.4	50
574	Abnormal β -catenin expression and reduced tumor-infiltrating T cells are related to poor progression in non-small cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 11572-11579.	0.5	1
575	Identification of Clinical and Tumor Microenvironment Characteristics of Hypoxia-Related Risk Signature in Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 757421.	1.6	5
576	Dual Photothermal/Chemotherapy of Melanoma Cells with Albumin Nanoparticles Carrying Indocyanine Green and Doxorubicin Leads to Immunogenic Cell Death. <i>Macromolecular Bioscience</i> , 2022, 22, e2100353.	2.1	10
577	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 810388.	2.2	9
578	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	2.5	38
579	Drug-induced sarcoidosis-like reactions. <i>The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders</i> , 2021, 41, 35-38.	0.1	0
580	A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24232.	0.9	3
581	Redox Metabolism-Associated Molecular Classification of Clear Cell Renal Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19.	1.9	4

#	ARTICLE	IF	CITATIONS
582	Harnessing dendritic cells for innovative therapeutic cancer vaccines. <i>Current Opinion in Oncology</i> , 2022, 34, 161-168.	1.1	10
583	Single-cell transcriptomics reveals a low CD8 ⁺ T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma. , 2022, 10, e004206.		27
584	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
585	Mesenchymal stromal cells equipped by IFN γ empower T cells with potent anti-tumor immunity. <i>Oncogene</i> , 2022, 41, 1866-1881.	2.6	9
586	Intron-Retention Neoantigen Load Predicts Favorable Prognosis in Pancreatic Cancer. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100124.	1.0	6
587	Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 6366.	1.7	10
588	Differential Gene Expression and Pathway Analysis in Melanoma Cell Lines Following MET and PD-L1 Downregulation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
589	The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. <i>Biomedicines</i> , 2022, 10, 822.	1.4	18
590	Current Advances in the Management of Adult Craniopharyngiomas. <i>Current Oncology</i> , 2022, 29, 1645-1671.	0.9	15
591	IL25 Enhanced Colitis-Associated Tumorigenesis in Mice by Upregulating Transcription Factor GLI1. <i>Frontiers in Immunology</i> , 2022, 13, 837262.	2.2	6
592	N6-Methyladenine-Related Signature for Immune Microenvironment and Response to Immunotherapy in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3525-3540.	0.8	5
594	Inhibition of renalase drives tumour rejection by promoting T cell activation. <i>European Journal of Cancer</i> , 2022, 165, 81-96.	1.3	2
595	Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2022, 42, 101748.	0.8	2
596	Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity. <i>Cancers</i> , 2021, 13, 6132.	1.7	29
597	Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 777775.	1.6	3
627	HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab. <i>Pathology and Oncology Research</i> , 2022, 28, 1610297.	0.9	5
628	Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	25
629	A novel oncolytic virus induces a regional cytokine storm and safely eliminates malignant ascites of colon cancer. <i>Cancer Medicine</i> , 2022, 11, 4297-4309.	1.3	5

#	ARTICLE	IF	CITATIONS
630	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
631	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
632	Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
633	Qin Huang formula enhances the effect of Adriamycin in B-cell lymphoma via increasing tumor infiltrating lymphocytes by targeting toll-like receptor signaling pathway. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, .	1.2	2
634	THEM6: A Novel Molecular Biomarker Predicts Tumor Microenvironment, Molecular Subtype, and Prognosis in Bladder Cancer. <i>Disease Markers</i> , 2022, 2022, 1-28.	0.6	1
635	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. , 2022, 10, e004879.		14
637	NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3
639	Systematic <scp>panâ€cancer</scp> analysis identifies <scp>RBM39</scp> as an immunological and prognostic biomarker. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4859-4871.	1.6	4
640	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. <i>Theranostics</i> , 2022, 12, 6106-6129.	4.6	14
641	Molekulares Tumorboard â€“ Nierenzellkarzinom. <i>Springer Reference Medizin</i> , 2022, , 1-4.	0.0	0
642	Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
643	Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor <scp>PDâ€L1</scp> , <scp>IDO</scp> , <scp>TIM</scp> â€³, <scp>FOXP3</scp> + and <scp>CD8</scp> expressions in patients with advanced esophageal squamous cell carcinoma. <i>Thoracic Cancer</i> , 0, , .	0.8	1
644	Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
645	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
646	Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	9
647	Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. <i>Clinical Radiology</i> , 2022, , .	0.5	0
648	Molecularly imprinted polymeric carriers for controlled drug release. , 2023, , 85-103.		1
649	Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment. <i>Cells</i> , 2022, 11, 3672.	1.8	15

#	ARTICLE	IF	CITATIONS
650	Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone. <i>Cancers</i> , 2023, 15, 48.	1.7	4
651	T cell-dependent bispecific antibodies alter organ-specific endothelial cell-T cell interaction. <i>EMBO Reports</i> , 0, , .	2.0	2
652	Drug-induced sarcoidosis-like reaction three months after BNT162b2 mRNA COVID-19 vaccination: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 0, 11, 177-186.	0.3	1
653	Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1294.	1.8	6
654	Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors. <i>Cancers</i> , 2023, 15, 289.	1.7	2
655	A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
656	Integrated analysis of the relation to tumor immune microenvironment and predicted value of <i>Stonin1</i> gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
657	Neutralization of NET-associated human ARG1 enhances cancer immunotherapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	14
659	Analysis of immunotherapeutic response-related signatures in esophageal squamous-cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
660	“Cold” colorectal cancer faces a bottleneck in immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 240-250.	0.8	3
661	An adverse tumor-protective effect of IDO1 inhibition. <i>Cell Reports Medicine</i> , 2023, 4, 100941.	3.3	7
662	Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment. <i>Scientific Reports</i> , 2023, 13, .	1.6	8
663	Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. , 2023, , 1-19.		0
664	Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2023, 29, 1938-1951.	3.2	2
665	From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma. <i>OncoTargets and Therapy</i> , 0, Volume 16, 227-232.	1.0	2
666	BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 751-764.	1.9	0
667	Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. <i>Cell Reports</i> , 2023, 42, 112364.	2.9	0
668	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. <i>Advances in Anatomic Pathology</i> , 2023, 30, 174-194.	2.4	0

#	ARTICLE	IF	CITATIONS
670	Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nature Reviews Clinical Oncology, 2023, 20, 408-422.	12.5	9
681	Molekulares Tumorboard â€œ Nierenzellkarzinom. Springer Reference Medizin, 2023, , 1337-1340.	0.0	0
691	CXCL9, CXCL10, CXCL11/CXCR3 Axis and Immune Activation. , 2023, , 271-289.		0
693	Precision Nutrition and Cancer. , 2024, , 277-298.		1
700	Role of biomarkers in assessing response to immune checkpoint inhibitors in cancer treatment. , 2024, , 281-303.		0